Research Article
The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Table 8
Gastric mucosal changes at EGD according to the administration of LDASA and the rate of H. pylori detection.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes: LDASA: low-dose acetylsalicylic acid. The percentage of patients with appropriate GM changes in the LDASA, non-NSAID+LDASA, and comparison groups was calculated from the total number of patients in the corresponding group. The percentage of H. pylori-positive patients was calculated from the number of those with appropriate GM changes in the LDASA, non- NSAID+LDASA, and comparison groups. Р1: comparison of the number of patients with and without appropriate GM changes in the comparison and LDASA groups. Р2: comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the comparison and LDASA groups. Р3: comparison of the number of patients with and without appropriate GM changes in the LDASA and non-LDASA groups. Р4: comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the LDASA and non-LDASA groups. |